Dapagliflozin

Routes
Oral (PO)
Half-Life (t½)
PO: 12.9h
Formula
C21H25ClO6
Molecular Weight
408.87 g/mol
PubChem CID
9887712
Aliases
Farxiga, Forxiga, BMS-512148

Pharmacological Mechanism

Selective SGLT2 inhibitor — first-in-class (approved EU 2012, US 2014). Mechanism + glucosuric output comparable to empagliflozin; slightly lower SGLT2:SGLT1 selectivity (~1400-fold). DAPA-HF established HFrEF benefit independent of diabetes status; DAPA-CKD established CKD progression reduction.

Half-Life & Elimination Curve (PO: 12.9h)

100%50%25%12.5%0%0h0×t½12.9h1×t½25.8h2×t½38.7h3×t½51.6h4×t½64.5h5×t½0×t½ (0h): 100% remaining (~44.3 µg/L)1×t½ (12.9h): 50% remaining (~22.1 µg/L)2×t½ (25.8h): 25% remaining (~11.1 µg/L)3×t½ (38.7h): 12.5% remaining (~5.53 µg/L)4×t½ (51.6h): 6.3% remaining (~2.77 µg/L)5×t½ (64.5h): 3.1% remaining (~1.38 µg/L)
Plasma (PO)t½ Decay (12.9h)
  • 0×t½0h100% (44.3 µg/L)
  • 1×t½12.9h50% (22.1 µg/L)
  • 2×t½25.8h25% (11.1 µg/L)
  • 3×t½38.7h12.5% (5.53 µg/L)
  • 4×t½51.6h6.3% (2.77 µg/L)
  • 5×t½64.5h3.1% (1.38 µg/L)
Elimination t½12.9h (PO)
Rate Constant (ke)0.0537 h⁻¹
Time to Peak (Tmax)54m
Est. Peak (Cmax)44.3 µg/L
Clearance (CL)6.02 L/h
97% Washout (5×t½)64.5h

Dosing Guidelines

Pharmacokinetic Parameters

Pathways It Modulates

Target Organ Systems

Interactions

Chemical Structure & Identifiers

References